Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03517488
Other study ID # XmAb20717-01
Secondary ID DUET-2
Status Completed
Phase Phase 1
First received
Last updated
Start date July 10, 2018
Est. completion date September 6, 2022

Study information

Verified date November 2022
Source Xencor, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD/RD and regimen of XmAb20717, to describe safety and tolerability, to assess PK and immunogenicity, and to preliminarily assess anti-tumor activity of XmAb20717 in subjects with selected advanced solid tumors.


Recruitment information / eligibility

Status Completed
Enrollment 150
Est. completion date September 6, 2022
Est. primary completion date June 1, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Histologically or cytologically confirmed diagnosis of one of the following advanced solid tumors: PART A (Dose Escalation Cohorts) 1. Melanoma; 2. Breast carcinoma that is estrogen receptor, progesterone receptor, and Her2 negative (triple-negative breast cancer; TNBC); 3. Hepatocellular carcinoma; 4. Urothelial carcinoma; 5. Squamous cell carcinoma of the head and neck; 6. Renal cell carcinoma (clear cell predominant type); 7. Microsatellite instability-high or mismatch repair deficient colorectal carcinoma or endometrial carcinoma; 8. Non-small cell lung carcinoma; 9. Gastric or gastroesophageal junction adenocarcinoma 10. Mesothelioma; 11. High-grade neuroendocrine carcinoma, including small cell carcinoma of the lung 12. Cervical cancer; 13. Squamous cell carcinoma of the anus PART B (Dose Expansion Cohorts): 1. Melanoma 2. Renal cell carcinoma (clear cell predominant type) 3. Non-small cell lung carcinoma 4. Castrate-resistant adenocarcinoma of the prostate, defined as progressive disease after surgical castration, or progression in the setting of medical androgen ablation with a castrate level of testosterone (< 50 ng/dL) 5. Nasopharyngeal carcinoma 6. Cholangiocarcinoma 7. Basal cell carcinoma 8. Squamous cell carcinoma of the anus 9. Mesothelioma 10. Ovarian or fallopian tube carcinoma 11. Malignant adnexal neoplasms (including, but not limited to, sebaceous carcinoma, trichilemmal carcinoma, pilomatrix carcinoma, eccrine carcinoma, hidradenocarcinoma, adnexal carcinoma with divergent differentiation, papillary digital eccrine adenocarcinoma, microcystic adnexal carcinoma, and clear cell eccrine carcinoma) 12. Thymoma 13. Thymic carcinoma 14. Squamous cell carcinoma of the penis 15. Neuroendocrine carcinoma 16. Vulvar cancer 17. Non-squamous cell salivary gland carcinoma (except adenoid cystic carcinoma) 18. Subjects with other solid tumors for which there is published evidence of anti-tumor activity with anti-PD1/PDL1 and/or anti-CTLA4-directed therapy but for which there is no FDA-approved anti-PD1/PDL1 or CTLA4-directed checkpoint inhibitor treatment may be eligible for Part B after approval by the Medical Monitor. - All subjects' cancer must have progressed after treatment with all standard therapies or have no appropriate available therapies. - Subjects, except those with adenocarcinoma of the prostate, must have measurable disease by RECIST 1.1. - Have available adequate archival formalin-fixed paraffin-embedded block(s)/slides containing tumor or adequate pre-dose fresh tumor biopsy tissue - ECOG performance status of 0 - 1 - Subjects with adenocarcinoma of the prostate must have evaluable disease (measurable or nonmeasurable lesions) by PCWG3. Exclusion Criteria: - Subjects currently receiving other anticancer therapies, with the exception of subjects with adenocarcinoma of the prostate, who may continue luteinizing hormone-releasing hormone (LHRH) analogue therapy. - Treatment with any CTLA4 antibody within 6 weeks of the start of study drug. - Treatment with nivolumab or any PDL1 or PDL2-directed antibody within 4 weeks of the start of study drug. - Treatment with pembrolizumab within 4 - 12 weeks of the start of study drug (cohort dependent). - Treatment with any other anticancer therapy within 2 weeks of the start of study drug (i.e., other immunotherapy, chemotherapy, radiation therapy, etc.). Subjects with prostate cancer may continue LHRH analogue therapy. - A life-threatening (Grade 4) immune-mediated AE related to prior immunotherapy. - Failure to recover from any immune-related toxicity from prior cancer therapy to = Grade 1, except if previous immune-related endocrinopathy is medically managed with hormone replacement therapy only. - Failure to recover from any other toxicity (other than immune-related toxicity) related to previous anticancer treatment to = Grade 2. - Have known active CNS metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable, ie, are without evidence of progression for at least 4 weeks by repeat imaging, are clinically stable, and without requirement of steroid treatment for at least 14 days prior to first dose of study treatment. - Active known or suspected autoimmune disease (except that subjects are permitted to enroll if they have vitiligo; type 1 diabetes mellitus or residual hypothyroidism due to an autoimmune condition that is treatable with hormone replacement therapy only; psoriasis, atopic dermatitis, or another autoimmune skin condition that is managed without systemic therapy; or arthritis that is managed without systemic therapy beyond oral acetaminophen and non-steroidal anti-inflammatory drugs). - Has any condition requiring systemic treatment with corticosteroids, prednisone equivalents, or other immunosuppressive medications within 14 days prior to first dose of study drug (except that inhaled or topical corticosteroids or brief courses of corticosteroids given for prophylaxis of contrast dye allergic response are permitted). - Receipt of an organ allograft. - Prior treatment with any checkpoint inhibitor therapy regimen that targets both PD1/L1 and CTLA-4.

Study Design


Related Conditions & MeSH terms

  • Anus Neoplasms
  • Basal Cell Carcinoma
  • Breast Carcinoma
  • Breast Neoplasms
  • Carcinoma
  • Carcinoma, Basal Cell
  • Carcinoma, Neuroendocrine
  • Carcinoma, Non-Small-Cell Lung
  • Carcinoma, Squamous Cell
  • Castration-Resistant Prostate Carcinoma
  • Cervical Cancer
  • Cholangiocarcinoma
  • Colorectal Carcinoma
  • Colorectal Neoplasms
  • Endometrial Carcinoma
  • Endometrial Neoplasms
  • Fallopian Tube Carcinoma
  • Gastric or Gastroesophageal Junction Adenocarcinoma
  • Hepatocellular Carcinoma
  • Lung Neoplasms
  • Malignant Adnexal Neoplasms
  • Melanoma
  • Mesothelioma
  • Mesothelioma, Malignant
  • Nasopharyngeal Carcinoma
  • Neuroendocrine Carcinoma
  • Non-small Cell Lung Carcinoma
  • Non-squamous Cell Salivary Gland Carcinoma
  • Ovarian Carcinoma
  • Renal Cell Carcinoma
  • Small Cell Lung Carcinoma
  • Solid Tumors With Published Evidence of Anti-tumor Activity With Anti-PD1/PDL1 and/or Anti-CTLA4-directed Therapy
  • Squamous Cell Carcinoma of Head and Neck
  • Squamous Cell Carcinoma of the Anus
  • Squamous Cell Carcinoma of the Head and Neck
  • Squamous Cell Carcinoma of the Penis
  • Thymic Carcinoma
  • Thymoma
  • Urothelial Carcinoma
  • Uterine Cervical Neoplasms
  • Vulvar Carcinoma
  • Vulvar Neoplasms

Intervention

Biological:
XmAb20717
Monoclonal bispecific antibody

Locations

Country Name City State
United States Emory University Atlanta Georgia
United States Emily Couric Clinical Cancer Center Charlottesville Virginia
United States University of Chicago Medicine Chicago Illinois
United States Karmanos Cancer Institute Detroit Michigan
United States The University of Kansas Clinical Research Center Fairway Kansas
United States The University of Texas MD Anderson Cancer Center Houston Texas
United States Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute Los Angeles California
United States UCLA Hematology-Oncology Clinic (Westwood) Los Angeles California
United States Columbia University Medical Center - Herbert Irving Pavilion New York New York
United States Laura and Isaac Perlmutter Cancer Center at NYU Langone New York New York
United States Hospital of the University of Pennsylvania Philadelphia Pennsylvania
United States UPMC Hillman Cancer Center Pittsburgh Pennsylvania
United States Providence Portland Medical Center Portland Oregon
United States University of Utah, Huntsman Cancer Institute Salt Lake City Utah
United States University of California San Diego Moores Cancer Center San Diego California
United States University of California San Francisco Medical Center San Francisco California
United States Seattle Cancer Care Alliance Seattle Washington

Sponsors (2)

Lead Sponsor Collaborator
Xencor, Inc. ICON plc

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Determine the safety and tolerability profile of XmAb20717 Treatment-related adverse events as assessed by CTCAE v4.03 56 Days
See also
  Status Clinical Trial Phase
Recruiting NCT04209491 - Interest of the Intervention of a Nurse Coordinator in Complex Care Pathway
Completed NCT03963206 - Cabozantinib toLERANCE Study in HepatoCellular Carcinoma (CLERANCE) Phase 4
Completed NCT03268499 - TACE Emulsion Versus Suspension Phase 2
Recruiting NCT05263830 - Glypican-3 as a Prognostic Factor in Patients With Hepatocellular Carcinoma Treated by Immunotherapy
Recruiting NCT05044676 - Immune Cells as a New Biomarker of Response in Patients Treated by Immunotherapy for Advanced Hepatocellular Carcinoma
Recruiting NCT05095519 - Hepatocellular Carcinoma Imaging Using PSMA PET/CT Phase 2
Recruiting NCT05497531 - Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers N/A
Completed NCT05068193 - A Clinical Trial to Compare the Pharmacokinetics and Bioequivalence of "BR2008" With "BR2008-1" in Healthy Volunteers Phase 1
Active, not recruiting NCT03781934 - A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations Phase 1/Phase 2
Terminated NCT03655613 - APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC Phase 1/Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT04242199 - Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors Phase 1
Completed NCT04401800 - Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma Phase 2
Withdrawn NCT05418387 - A Social Support Intervention to Improve Treatment Among Hispanic Kidney and Liver Cancer Patients in Arizona N/A
Active, not recruiting NCT04039607 - A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma Phase 3
Terminated NCT03970616 - A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma Phase 1/Phase 2
Recruiting NCT06239155 - A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT04118114 - Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors Phase 2
Recruiting NCT03642561 - Evaluation the Treatment Outcome for RFA in Patients With BCLC Stage B HCC in Comparison With TACE Phase 2/Phase 3
Completed NCT03222076 - Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer Phase 2